无阿片麻醉在心脏手术中的随机临床试验:OFACAR研究
OFACAR为法国两中心随机盲法优势试验,纳入320例体外循环择期心脏手术成人,比较无阿片麻醉(氯胺酮、地塞米松、利多卡因、硫酸镁)与舒芬太尼麻醉。无阿片组主要复合终点(术后30天内神经、呼吸、心血管、肾脏并发症和/或死亡)发生率为75.4%,对照组为84.5%(RR 0.90,95%CI 0.80-0.99,P=0.049)。作者认为结果需更大样本验证。
要点
- 无阿片麻醉组主要复合终点风险低于阿片麻醉组(RR 0.90,95%CI 0.80-0.99,P=0.049)。
- 无阿片组心血管并发症(RR 0.86,95%CI 0.74-0.99,P=0.031)和消化道并发症(RR 0.22,95%CI 0.08-0.65,P=0.007)均降低。
- 主要终点脆弱指数为1,作者认为结果属假说生成,需更大试验证实。
核心结论
- 在体外循环心脏手术患者中,与舒芬太尼阿片麻醉相比,无阿片麻醉可能降低术后30天复合并发症发生率(RR 0.90,95%CI 0.80-0.99,P=0.049)。
- 主要终点脆弱指数为1,作者认为该结果应视为假说生成,需更大规模试验确认。
研究设计与样本
- 随机、对照、盲法、多中心优势试验,在法国两家三级大学医院开展,时间为2021年8月至2023年12月。
- 纳入320例体外循环择期心脏手术成人患者,随机分为无阿片麻醉组(n=159)和舒芬太尼阿片麻醉组(n=161)。
- 无阿片麻醉方案为静脉给予氯胺酮、地塞米松、利多卡因和硫酸镁。
主要发现
- 主要复合终点(术后30天内神经、呼吸、心血管、肾脏并发症和/或死亡)在无阿片组发生120例(75.4%),对照组136例(84.5%)(RR 0.90,95%CI 0.80-0.99,P=0.049)。
- 心血管并发症发生率无阿片组64.2% vs 对照组75.2%(RR 0.86,95%CI 0.74-0.99,P=0.031),其中术后心肌损伤为61.6% vs 72.1%。
- 消化道并发症发生率无阿片组2.5% vs 对照组11.2%(RR 0.22,95%CI 0.08-0.65,P=0.007)。
- 无阿片组无死亡,对照组死亡6例(P=0.014)。
临床怎么用
- 对于体外循环心脏手术成人患者,可考虑采用以氯胺酮、地塞米松、利多卡因和硫酸镁为基础的无阿片麻醉方案,但需注意主要终点脆弱指数为1,证据尚不稳健。
局限性
- 作者指出主要终点脆弱指数为1,结果应视为假说生成,需更大规模试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid-free anesthesia (OFA) may reduce postoperative complications in cardiac surgery, but evidence from large randomized trials is limited. METHODS: This study was a randomized, controlled, blinded, multicenter superiority trial at two tertiary university hospitals in France from August 2021 to December 2023. The study enrolled 320 adult patients undergoing elective cardiac surgery with cardiopulmonary bypass. Patients were randomized to receive either OFA (n = 159) consisting of intravenous ketamine, dexamethasone, lidocaine, and magnesium sulfate, or opioid anesthesia with sufentanil (n = 161). The primary outcome was a composite of postoperative neurologic, respiratory, cardiovascular, or renal complications and/or death within 30 days after surgery. RESULTS: Among 320 participants (mean age, 66.4 ± 10.5 yr; 247 men [77.2%]), the primary outcome occurred in 120 patients (75.4%) in the OFA group compared with 136 patients (84.5%) in the control group (risk ratio [RR], 0.90; 95% CI, 0.80 to 0.99; P = 0.049). The fragility index for the primary outcome was 1. OFA was associated with significant reductions in cardiovascular complications (64.2% vs . 75.2%; RR, 0.86; 95% CI, 0.74 to 0.99; P = 0.031), particularly postoperative myocardial damage (61.6% vs . 72.1%), and digestive complications (2.5% vs . 11.2%; RR, 0.22; 95% CI, 0.08 to 0.65; P = 0.007). No death occurred in the OFA group compared with six deaths in the control group ( P = 0.014). CONCLUSIONS: In patients undergoing cardiac surgery with cardiopulmonary bypass, opioid-free anesthesia may reduce composite postoperative complications compared with opioid anesthesia. The primary endpoint composite fragility index indicates that these results should be considered hypothesis generating and warrant confirmation in larger trials.
引用
- Guinot PG, Besch G, Jonval L, et al. Opioid-free Anesthesia in Cardiac Surgery: The OFACAR Randomized Clinical Trial. Anesthesiology. 2026. PMID: 42190101. doi:10.1097/ALN.0000000000006164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。